Australian company Immutep has announced positive efficacy and safety results from the TACTI-003 Phase 2b trial evaluating its eftilagimod alpha in combination with MSD’s KEYTRUDA. …
Immutep says its candidate in combination with Keytruda delivered positive efficacy and safety profile
September 16, 2024 Latest NewsAustralian Biotech
Latest Video
New Stories
-
Clear political leadership delivers green shoots in New Zealand
September 18, 2024 - - Latest News -
AusBiotech pays tribute to a leading figure in the creation of Australia's biotech sector
September 18, 2024 - - Latest News -
Pharmac continues to invest its post-Budget funding boost
September 18, 2024 - - Latest News -
The HTA Review report - 'Red Flag' number four of five
September 18, 2024 - - Latest News -
Wesfarmers Health announces plan to build new fulfilment centre in Cairns
September 17, 2024 - - Latest News -
Medicines Australia launches next phase of campaign in PM's electorate
September 17, 2024 - - Latest News -
The HTA Review report - 'Red Flag' number three of five
September 17, 2024 - - Latest News